Published in

Taylor and Francis Group, Expert Review of Clinical Immunology, p. 1-10, 2023

DOI: 10.1080/1744666x.2023.2268284

Links

Tools

Export citation

Search in Google Scholar

Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus

Journal article published in 2023 by Noémie Gensous ORCID, Estibaliz Lazaro ORCID, Patrick Blanco ORCID, Christophe Richez ORCID
Distributing this paper is prohibited by the publisher
Distributing this paper is prohibited by the publisher

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO